MedPath
Found 12 clinical trials|View Analysis
Sort by:

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

Phase 1
Conditions
Metastatic Castrate-Resistant Prostate Cancer
mCRPC (Metastatic Castration-resistant Prostate Cancer)
Interventions
Drug: XNW5004
Drug: enzalutamide
First Posted Date
2024-11-25
Last Posted Date
2024-11-25
Lead Sponsor
Evopoint Biosciences Inc.
Target Recruit Count
307
Registration Number
NCT06702995
Locations
🇨🇳

Cancer Hosipital of Shandong First Medical University,440 Jiyan Road, Jinan City, Shandong Province, Jinan, Shandong, China

🇨🇳

270 Dongan Road, Shanghai, Shanghai, Shanghai, China

To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Phase 2
Not yet recruiting
Conditions
Relapsed/Refractory Peripheral T Cell Lymphoma
Interventions
Drug: XNW5004 tablets
First Posted Date
2024-11-25
Last Posted Date
2024-11-25
Lead Sponsor
Evopoint Biosciences Inc.
Target Recruit Count
50
Registration Number
NCT06702605

To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors

Phase 1
Recruiting
Conditions
Advanced Tumor
Lymphoma
Interventions
Drug: XNW5004 tablets
First Posted Date
2024-08-16
Last Posted Date
2024-08-16
Lead Sponsor
Evopoint Biosciences Inc.
Target Recruit Count
176
Registration Number
NCT06558513
Locations
🇨🇳

Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, China

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Phase 1
Recruiting
Conditions
Carcinoma
Urothelial Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-small Cell Lung Cancer
Prostate Cancer
Cervical Cancer
Other Solid Tumors
Small-cell Lung Cancer
Interventions
First Posted Date
2023-09-05
Last Posted Date
2024-02-23
Lead Sponsor
Evopoint Biosciences Inc.
Target Recruit Count
204
Registration Number
NCT06022757
Locations
🇨🇳

Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guodong Province, China

Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)

Phase 3
Not yet recruiting
Conditions
Complicated Urinary Tract Infection Including Acute Pyelonephritis
Interventions
Drug: Combination of Imipenem/Cilastatin and XNW4107
Drug: Meropenem
First Posted Date
2022-01-24
Last Posted Date
2023-02-16
Lead Sponsor
Evopoint Biosciences Inc.
Target Recruit Count
780
Registration Number
NCT05204368
Locations
🇺🇸

University of Maryland Medical Center, Baltimore, Maryland, United States

Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)

Phase 3
Recruiting
Conditions
Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Interventions
Drug: Imipenem/Cilastatin/Relebactam
Drug: Combination of Imipenem/Cilastatin and XNW4107
First Posted Date
2022-01-24
Last Posted Date
2023-03-08
Lead Sponsor
Evopoint Biosciences Inc.
Target Recruit Count
450
Registration Number
NCT05204563
Locations
🇺🇸

Jackson Memorial Hospital (JMH) - Ryder Trauma Center, Miami, Florida, United States

🇫🇷

Groupe Hospitalier Paris Saint-Joseph, Paris, France

🇫🇷

Hôpital Foch, Suresnes, ILE DE France, France

and more 32 locations

Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects

Phase 1
Completed
Conditions
Bacterial Infections
Interventions
Drug: XNW4107, Imipenem/Cilastatin
First Posted Date
2021-03-17
Last Posted Date
2023-02-16
Lead Sponsor
Evopoint Biosciences Inc.
Target Recruit Count
21
Registration Number
NCT04802863
Locations
🇺🇸

Pulmonary Associates PA, Phoenix, Arizona, United States

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

Phase 1
Completed
Conditions
Bacterial Infections
Interventions
Drug: XNW4107
Drug: placebo
Drug: Imipenem/Cilastatin
First Posted Date
2021-03-16
Last Posted Date
2023-02-16
Lead Sponsor
Evopoint Biosciences Inc.
Target Recruit Count
24
Registration Number
NCT04801043
Locations
🇺🇸

Orlando Clinical Research Center (OCRC), Orlando, Florida, United States

Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function

Phase 1
Completed
Conditions
Bacterial Infections
Interventions
Drug: XNW4107, Imipenem/Cilastatin
First Posted Date
2021-03-08
Last Posted Date
2023-02-16
Lead Sponsor
Evopoint Biosciences Inc.
Target Recruit Count
39
Registration Number
NCT04787562
Locations
🇺🇸

Division of Clinical Pharmacology (DCP), University of Miami, Miami, Florida, United States

🇺🇸

Orlando Clinical Research Center (OCRC), Orlando, Florida, United States

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

Phase 1
Completed
Conditions
Bacterial Infections
Interventions
Drug: XNW4107
First Posted Date
2020-07-22
Last Posted Date
2023-02-16
Lead Sponsor
Evopoint Biosciences Inc.
Target Recruit Count
88
Registration Number
NCT04482569
Locations
🇺🇸

Pharmaron CPC, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath